Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 46

1.

A phase I clinical study of autologous dendritic cell therapy in patients with relapsed or refractory multiple myeloma.

Jung SH, Lee HJ, Lee YK, Yang DH, Kim HJ, Rhee JH, Emmrich F, Lee JJ.

Oncotarget. 2017 Jun 20;8(25):41538-41548. doi: 10.18632/oncotarget.14582.

2.

Milestones of Hematopoietic Stem Cell Transplantation - From First Human Studies to Current Developments.

Juric MK, Ghimire S, Ogonek J, Weissinger EM, Holler E, van Rood JJ, Oudshoorn M, Dickinson A, Greinix HT.

Front Immunol. 2016 Nov 9;7:470. eCollection 2016. Review.

3.

Recent advances in understanding multiple myeloma.

Dhakal B, Girnius S, Hari P.

F1000Res. 2016 Aug 23;5. pii: F1000 Faculty Rev-2053. doi: 10.12688/f1000research.8777.1. eCollection 2016. Review.

4.

Utilizing cell-based therapeutics to overcome immune evasion in hematologic malignancies.

Sun C, Dotti G, Savoldo B.

Blood. 2016 Jun 30;127(26):3350-9. doi: 10.1182/blood-2015-12-629089. Epub 2016 May 20. Review.

5.

The Role of Immunotherapy in Multiple Myeloma.

Kocoglu M, Badros A.

Pharmaceuticals (Basel). 2016 Jan 14;9(1). pii: E3. doi: 10.3390/ph9010003. Review.

6.

Multiple Myeloma, Version 2.2016: Clinical Practice Guidelines in Oncology.

Anderson KC, Alsina M, Atanackovic D, Biermann JS, Chandler JC, Costello C, Djulbegovic B, Fung HC, Gasparetto C, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kassim A, Krishnan AY, Kumar SK, Liedtke M, Lunning M, Raje N, Singhal S, Smith C, Somlo G, Stockerl-Goldstein K, Treon SP, Weber D, Yahalom J, Shead DA, Kumar R; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2015 Nov;13(11):1398-435.

7.

NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma.

Rapoport AP, Stadtmauer EA, Binder-Scholl GK, Goloubeva O, Vogl DT, Lacey SF, Badros AZ, Garfall A, Weiss B, Finklestein J, Kulikovskaya I, Sinha SK, Kronsberg S, Gupta M, Bond S, Melchiori L, Brewer JE, Bennett AD, Gerry AB, Pumphrey NJ, Williams D, Tayton-Martin HK, Ribeiro L, Holdich T, Yanovich S, Hardy N, Yared J, Kerr N, Philip S, Westphal S, Siegel DL, Levine BL, Jakobsen BK, Kalos M, June CH.

Nat Med. 2015 Aug;21(8):914-921. doi: 10.1038/nm.3910. Epub 2015 Jul 20.

8.

Establishment of a murine graft-versus-myeloma model using allogeneic stem cell transplantation.

Binsfeld M, Beguin Y, Belle L, Otjacques E, Hannon M, Briquet A, Heusschen R, Drion P, Zilberberg J, Bogen B, Baron F, Caers J.

PLoS One. 2014 Nov 21;9(11):e113764. doi: 10.1371/journal.pone.0113764. eCollection 2014. Erratum in: PLoS One. 2015;10(2):e0117643.

9.

Non-traditional CD4+CD25-CD69+ regulatory T cells are correlated to leukemia relapse after allogeneic hematopoietic stem cell transplantation.

Zhao XS, Wang XH, Zhao XY, Chang YJ, Xu LP, Zhang XH, Huang XJ.

J Transl Med. 2014 Jul 1;12:187. doi: 10.1186/1479-5876-12-187.

10.

Combination immunotherapy after ASCT for multiple myeloma using MAGE-A3/Poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and costimulated autologous T cells.

Rapoport AP, Aqui NA, Stadtmauer EA, Vogl DT, Xu YY, Kalos M, Cai L, Fang HB, Weiss BM, Badros A, Yanovich S, Akpek G, Tsao P, Cross A, Mann D, Philip S, Kerr N, Brennan A, Zheng Z, Ruehle K, Milliron T, Strome SE, Salazar AM, Levine BL, June CH.

Clin Cancer Res. 2014 Mar 1;20(5):1355-65. doi: 10.1158/1078-0432.CCR-13-2817. Epub 2014 Feb 11.

11.

CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma.

Chu J, Deng Y, Benson DM, He S, Hughes T, Zhang J, Peng Y, Mao H, Yi L, Ghoshal K, He X, Devine SM, Zhang X, Caligiuri MA, Hofmeister CC, Yu J.

Leukemia. 2014 Apr;28(4):917-27. doi: 10.1038/leu.2013.279. Epub 2013 Sep 26.

12.

Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation: part II. Autologous Transplantation-novel agents and immunomodulatory strategies.

Avigan D, Hari P, Battiwalla M, Bishop MR, Giralt SA, Hardy NM, Kröger N, Wayne AS, Hsu KC.

Biol Blood Marrow Transplant. 2013 Dec;19(12):1661-9. doi: 10.1016/j.bbmt.2013.08.011. Epub 2013 Sep 7.

13.

Cellular therapy following allogeneic stem-cell transplantation.

Rager A, Porter DL.

Ther Adv Hematol. 2011 Dec;2(6):409-28. doi: 10.1177/2040620711412416.

14.

Allogeneic hematopoietic cell transplantation for consolidation of VGPR or CR for newly diagnosed multiple myeloma.

Nishihori T, Ochoa-Bayona JL, Kim J, Pidala J, Shain K, Baz R, Sullivan D, Jim HS, Anasetti C, Alsina M.

Bone Marrow Transplant. 2013 Sep;48(9):1179-84. doi: 10.1038/bmt.2013.37. Epub 2013 Apr 1.

15.

WT1-specific T-cell responses in high-risk multiple myeloma patients undergoing allogeneic T cell-depleted hematopoietic stem cell transplantation and donor lymphocyte infusions.

Tyler EM, Jungbluth AA, O'Reilly RJ, Koehne G.

Blood. 2013 Jan 10;121(2):308-17. doi: 10.1182/blood-2012-06-435040. Epub 2012 Nov 16.

16.

Late relapses following reduced intensity allogeneic transplantation in patients with multiple myeloma: a long-term follow-up study.

Sahebi F, Shen Y, Thomas SH, Rincon A, Murata-Collins J, Palmer J, Krishnan AY, Karanes C, Htut M, Somlo G, Forman SJ.

Br J Haematol. 2013 Jan;160(2):199-206. doi: 10.1111/bjh.12123. Epub 2012 Nov 15.

17.

Fifty years of melphalan use in hematopoietic stem cell transplantation.

Bayraktar UD, Bashir Q, Qazilbash M, Champlin RE, Ciurea SO.

Biol Blood Marrow Transplant. 2013 Mar;19(3):344-56. doi: 10.1016/j.bbmt.2012.08.011. Epub 2012 Aug 24. Review.

18.

Novel strategies for immunotherapy in multiple myeloma: previous experience and future directions.

Danylesko I, Beider K, Shimoni A, Nagler A.

Clin Dev Immunol. 2012;2012:753407. doi: 10.1155/2012/753407. Epub 2012 May 10. Review.

19.

Cellular immunotherapy using dendritic cells against multiple myeloma.

Nguyen-Pham TN, Lee YK, Lee HJ, Kim MH, Yang DH, Kim HJ, Lee JJ.

Korean J Hematol. 2012 Mar;47(1):17-27. doi: 10.5045/kjh.2012.47.1.17. Epub 2012 Mar 28.

20.

Allo-SCT for multiple myeloma: a review of outcomes at a single transplant center.

Bensinger W, Rotta M, Storer B, Chauncey T, Holmberg L, Becker P, Sandmaier BM, Storb R, Maloney D.

Bone Marrow Transplant. 2012 Oct;47(10):1312-7. doi: 10.1038/bmt.2012.1. Epub 2012 Feb 13.

Supplemental Content

Support Center